Name | Title | Contact Details |
---|
Founded in 2006, Ocular Therapeutix is a fast-growing, aspiring leader in the biopharmaceutical industry. The company has a clear vision – to improve current therapeutic options in ophthalmology by encapsulating previously approved therapeutic agents in our novel hydrogel to provide a sustained delivery of drugs to the eye. We are reframing the industry with new modalities for ophthalmic therapies. As a small company, our employees are provided the unique opportunity to help build the foundation of the business as it grows. We strongly believe that our success is contingent upon the achievements of our employees. We strive to create a collaborative, challenging environment that encourages individuals to bring success to their career and the company. Through the use of our proprietary hydrogel technology, we strive to offer superior products that improve the world’s vision.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,400 people across 40 countries.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Integrated Medical, Inc. is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quality Home Care Providers is a Leonia, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.